IPO registrations (S-1, F-1) · Registrants
Citius Pharmaceuticals, Inc.
- SEC CIK
- 1506251 · filings on EDGAR ↗
- Former names
- Trail One, Inc. (2010–2014); TrailOne, Inc. (2010–2011)
- Registration
- Form S-1, first filed 2010-11-23, last 2020-06-05; 11 initial registrations, 19 amendments
- Outcome
- Final prospectus filed 2017-08-04; declared effective 2011-07-12
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 11 COMMERCE DRIVE, 1ST FLOOR, Cranford, NJ 07016
- EIN
- 27-3425913
- Ticker
- CTXR (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Citius Pharmaceuticals, Inc. on the corporate pages
Offering terms
- Final price
- $4.12 per share (424B4 filed 2017-08-04, an initial public offering)
- Shares sold
- 1,648,484
- Gross proceeds
- $6,799,996 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CTXR
- Lead underwriters
- Aegis Capital
- Syndicate
- Dawson James
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Citius Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- SEC filer: Citius Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- Person page: Dennis M Mcgrath Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Leonard L Mazur Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 53
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2010-11-23 | S-1 | S-1 (registration) | TrailOne, Inc. | 0001019687-10-004215 ↗ |
| 2011-01-21 | S-1/A | S-1/A (amendment) | TrailOne, Inc. | 0001019687-11-000229 ↗ |
| 2011-03-16 | S-1/A | S-1/A (amendment) | Trail One, Inc. | 0001019687-11-000889 ↗ |
| 2011-04-19 | S-1/A | S-1/A (amendment) | Trail One, Inc. | 0001019687-11-001262 ↗ |
| 2011-05-09 | S-1/A | S-1/A (amendment) | Trail One, Inc. | 0001019687-11-001522 ↗ |
| 2011-06-02 | S-1/A | S-1/A (amendment) | Trail One, Inc. | 0001019687-11-001860 ↗ |
| 2011-06-23 | S-1/A | S-1/A (amendment) | Trail One, Inc. | 0001019687-11-002039 ↗ |
| 2011-07-07 | S-1/A | S-1/A (amendment) | Trail One, Inc. | 0001019687-11-002184 ↗ |
| 2011-07-12 | EFFECT | EFFECT (declared effective) | Trail One, Inc. | 9999999995-11-002099 ↗ |
| 2015-09-11 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001477932-15-005841 ↗ |
| 2015-10-16 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-15-006456 ↗ |
| 2015-11-04 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-15-006751 ↗ |
| 2015-12-29 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-15-007801 ↗ |
| 2016-01-12 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-16-007987 ↗ |
| 2016-01-21 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-16-003568 ↗ |
| 2017-02-10 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001477932-17-000681 ↗ |
| 2017-04-04 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-17-001550 ↗ |
| 2017-04-11 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-17-000790 ↗ |
| 2017-05-12 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001477932-17-002202 ↗ |
| 2017-07-03 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-17-003147 ↗ |
| 2017-07-13 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-17-003292 ↗ |
| 2017-07-24 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-17-003476 ↗ |
| 2017-07-28 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001477932-17-003562 ↗ |
| 2017-08-02 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-17-002021 ↗ |
| 2017-08-04 | 424B4 | 424B4 (final prospectus) | Citius Pharmaceuticals, Inc. | 0001477932-17-003653 ↗ |
| 2017-12-15 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-17-003236 ↗ |
| 2018-01-12 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001213900-18-000481 ↗ |
| 2018-01-19 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-18-000161 ↗ |
| 2018-01-30 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001213900-18-001021 ↗ |
| 2018-02-01 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-18-000313 ↗ |
| 2018-04-20 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001213900-18-004782 ↗ |
| 2018-04-26 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-18-000941 ↗ |
| 2018-07-27 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001213900-18-009773 ↗ |
| 2018-08-06 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001213900-18-010251 ↗ |
| 2018-08-08 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-18-002046 ↗ |
| 2018-08-10 | 424B4 | 424B4 (final prospectus) | Citius Pharmaceuticals, Inc. | 0001213900-18-010670 ↗ |
| 2019-04-17 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001213900-19-006592 ↗ |
| 2019-04-26 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-19-000862 ↗ |
| 2019-09-13 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001213900-19-017988 ↗ |
| 2019-09-20 | S-1/A | S-1/A (amendment) | Citius Pharmaceuticals, Inc. | 0001213900-19-018533 ↗ |
| 2019-09-24 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-19-002163 ↗ |
| 2019-09-26 | 424B4 | 424B4 (final prospectus) | Citius Pharmaceuticals, Inc. | 0001213900-19-019012 ↗ |
| 2020-04-10 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001213900-20-008985 ↗ |
| 2020-04-24 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-20-000856 ↗ |
| 2020-06-05 | S-1 | S-1 (registration) | Citius Pharmaceuticals, Inc. | 0001213900-20-014231 ↗ |
| 2020-06-12 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-20-001419 ↗ |
| 2020-09-25 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-20-002581 ↗ |
| 2020-09-30 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-20-002620 ↗ |
| 2021-02-05 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-21-000477 ↗ |
| 2021-04-16 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-21-001468 ↗ |
| 2021-05-20 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-21-002046 ↗ |
| 2021-07-08 | EFFECT | EFFECT (declared effective) | Citius Pharmaceuticals, Inc. | 9999999995-21-002676 ↗ |
| 2021-07-23 | 424B4 | 424B4 (final prospectus) | Citius Pharmaceuticals, Inc. | 0001213900-21-038381 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-07-28 | S-1/A | registration statement | 1,489,758 | - | Nasdaq CTXR | 2 | primary document; shares headline, cover names 2 | document ↗ | ||
| 2017-08-04 | 424B4 | final prospectus | $4.12 | 1,648,484 | $6,799,996 | Nasdaq CTXR | 2 | primary document; price sentence, shares headline, proceeds computed, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| HOLUBIAK MYRON Z | Director; Director,Officer; Director,Officer,TenPercentOwner | President and CEO; Vice Chairman | 18 | 2015–2025 | |
| Mazur Leonard L | Director; Director,Officer; Director,Officer,TenPercentOwner | CEO, President and COO; Chief Executive Officer; Executive Chairman | 23 | 2015–2025 | person page Fuzzy |
| Dutia Suren G | Director | 12 | 2015–2024 | ||
| SAFIR HOWARD | Director | 11 | 2016–2022 | ||
| Webb Carol | Director | 14 | 2016–2024 | ||
| Kane William | Director | 11 | 2016–2022 | ||
| Holuka Eugene Myron | Director | 14 | 2016–2024 | ||
| Bartushak Jaime | Officer | Chief Financial Officer | 9 | 2017–2024 | |
| Czuczman Myron | Officer | Chief Medical Officer | 6 | 2020–2024 | |
| MCGRATH DENNIS M | Director | 4 | 2023–2024 | person page Fuzzy | |
| Smith Robert Joseph | Director | 3 | 2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-02-01 | Citius Pharmaceuticals, Inc. | Pharmaceuticals | $20,000,012 | $20,000,012 | 7 | 1 |
| 2020-05-19 | Citius Pharmaceuticals, Inc. | Pharmaceuticals | $3,529,412 | $220,588 | 5 | 1 |
| 2019-04-08 | Citius Pharmaceuticals, Inc. | Pharmaceuticals | $428,803 | $428,803 | 3 | 1 |
| 2018-05-22 | Citius Pharmaceuticals, Inc. | Pharmaceuticals | $83,688 | $83,688 | 2 | 1 |
| 2017-12-20 | Citius Pharmaceuticals, Inc. | Pharmaceuticals | $40,011 | $40,011 | 8 | 1 |
| 2016-12-08 | Citius Pharmaceuticals, Inc. | Pharmaceuticals | $6,000,000 | $549,900 | 9 | 2 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Citius Pharmaceuticals, Inc. | NJ | Form D private offerings | CIK (EXACT) |
| IPO registrant | CITIUS ONCOLOGY, INC. | NJ | IPO registrations (S-1, F-1) | same street address and ZIP code, 11 COMMERCE DR 1ST FL 07016 (FUZZY: a shared address, not proof of a shared organization) |
| Paying company | Citius Pharmaceuticals, Inc. | NJ | Open Payments (drug and device company payments) | name and state |
| SEC filer | Citius Pharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Citius Pharmaceuticals, Inc. | NJ | Trademarks (USPTO) | name and state |
| Person page | Dennis M Mcgrath | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Leonard L Mazur | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, NJ first:
- KOS PHARMACEUTICALS INC NJ
- NOVADEL PHARMA INC NJ
- ELITE PHARMACEUTICALS INC /NV/ NJ
- MEMORY PHARMACEUTICALS CORP NJ
- PHIBRO ANIMAL HEALTH CORP NJ
- PTC THERAPEUTICS, INC. NJ
- ADVANCED NUTRACEUTICALS INC NJ
- Ayala Pharmaceuticals, Inc. NJ
- INSMED Inc NJ
- Sonnet BioTherapeutics Holdings, Inc. NJ
In other datasets, the same topic (Health) in NJ:
- Nonprofit: 1ST CEREBRAL PALSY OF NEW JERSEY INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health